BACKGROUND: Many patients with asthma have uncontrolled disease despite treatment with inhaled glucocorticoids. One potential cause of the variability in r...
Several monoclonal antibodies have been developed to target molecules in the inflammatory pathways of asthma. Lebrikizumab was developed to bind and inhibit IL-23 (7). Periostin, a matricellular protein, is secreted by bronchial epitheli...
Several monoclonal antibodies have been developed to target molecules in the inflammatory pathways of asthma. Lebrikizumab was developed to bind and inhibit IL-23 (7). Periostin, a matricellular protein, is secreted by bronchial epitheli...
Background: Asthma is a disease with marked heterogeneity in its clinical course and response to treatment. IL-13 is central to type 2 inflammation, which ...
Background Asthma is a disease with marked heterogeneity in its clinical course and response to treatment. IL-13 is central to type 2 inflammation, which c...
